Role of somatic cancer mutations in human protein lysine methyltransferases

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1846, Issue 2, 2014, Pages 366-379

  Kudithipudi, Srikanth ^a   Jeltsch, Albert ^a  

^a UNIVERSITY OF STUTTGART   (Germany)

Author keywords

Enzyme mechanism; Histone methylation; Lysine methylation; Protein lysine methyltransferase; Somatic cancer mutations

Indexed keywords

CELL PROTEIN; DOT1L PROTEIN; HISTONE H3; METHYLTRANSFERASE; MIXED LINEAGE LEUKEMIA PROTEIN; MLL1 PROTEIN; MLL4 PROTEIN; NSD PROTEIN; PROTEIN LYSINE METHYLTRANSFERASES; SETD2 PROTEIN; SMYD PROTEIN; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; EZH2 PROTEIN, HUMAN; HISTONE LYSINE METHYLTRANSFERASE; POLYCOMB REPRESSIVE COMPLEX 2; SET2 PROTEIN, HUMAN;

CARCINOGENESIS; CHROMATIN STRUCTURE; DNA MODIFICATION; EPIGENETICS; GAIN OF FUNCTION MUTATION; HUMAN; LOSS OF FUNCTION MUTATION; ONCOLOGICAL PARAMETERS; PROTEIN FUNCTION; REVIEW; SOMATIC CANCER MUTATION; SOMATIC MUTATION; GENETICS; MUTATION; NEOPLASM; PHYSIOLOGY;

HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; MUTATION; NEOPLASMS; POLYCOMB REPRESSIVE COMPLEX 2;

EID: 84907646535     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2014.08.002     Document Type: Review

References (147)

1. Kouzarides T. Chromatin modifications and their function. Cell 2007, 128:693-705.
2. Margueron R., Reinberg D. Chromatin structure and the inheritance of epigenetic information. Nat. Rev. Genet. 2010, 11:285-296.
3. Bannister A.J., Kouzarides T. Regulation of chromatin by histone modifications. Cell Res. 2011, 21:381-395.
4. Tan M., Luo H., Lee S., Jin F., Yang J.S., Montellier E., Buchou T., Cheng Z., Rousseaux S., Rajagopal N., Lu Z., Ye Z., Zhu Q., Wysocka J., Ye Y., Khochbin S., Ren B., Zhao Y. Identification of 67 histone marks and histone lysine crotonylation as a new type of histone modification. Cell 2011, 146:1016-1028.
5. Jurkowska R.Z., Jurkowski T.P., Jeltsch A. Structure and function of mammalian DNA methyltransferases. Chembiochem 2011, 12:206-222.
6. Jeltsch A., Jurkowska R.Z. New concepts in DNA methylation. Trends Biochem. Sci. 2014, 39:310-318.
7. Dawson M.A., Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell 2012, 150:12-27.
8. Chi P., Allis C.D., Wang G.G. Covalent histone modifications-miswritten, misinterpreted and mis-erased in human cancers. Nat. Rev. Cancer 2010, 10:457-469.
9. Bonasio R., Tu S., Reinberg D. Molecular signals of epigenetic states. Science 2010, 330:612-616.
10. Rothbart S.B., Strahl B.D. Interpreting the language of histone and DNA modifications. Biochim. Biophys. Acta 2014, 1839:627-643.
11. Cheng X., Collins R.E., Zhang X. Structural and sequence motifs of protein (histone) methylation enzymes. Annu. Rev. Biophys. Biomol. Struct. 2005, 34:267-294.
12. Del Rizzo P.A., Trievel R.C. Molecular basis for substrate recognition by lysine methyltransferases and demethylases. Biochim. Biophys. Acta 2014, (in press).
13. Cui K., Zang C., Roh T.Y., Schones D.E., Childs R.W., Peng W., Zhao K. Chromatin signatures in multipotent human hematopoietic stem cells indicate the fate of bivalent genes during differentiation. Cell Stem Cell 2009, 4:80-93.
14. Voigt P., Tee W.W., Reinberg D. A double take on bivalent promoters. Genes Dev. 2013, 27:1318-1338.
15. Klose R.J., Zhang Y. Regulation of histone methylation by demethylimination and demethylation. Nat. Rev. Mol. Cell Biol. 2007, 8:307-318.
16. Tian X., Zhang S., Liu H.M., Zhang Y.B., Blair C.A., Mercola D., Sassone-Corsi P., Zi X. Histone lysine-specific methyltransferases and demethylases in carcinogenesis: new targets for cancer therapy and prevention. Curr. Cancer Drug Targets 2013, 13:558-579.
17. Thinnes C.C., England K.S., Kawamura A., Chowdhury R., Schofield C.J., Hopkinson R.J. Targeting histone lysine demethylases - progress, challenges, and the future. Biochim. Biophys. Acta 2014, (in press).
18. Wong K.M., Hudson T.J., McPherson J.D. Unraveling the genetics of cancer: genome sequencing and beyond. Annu. Rev. Genomics Hum. Genet. 2011, 12:407-430.
19. Baylin S.B., Jones P.A. A decade of exploring the cancer epigenome - biological and translational implications. Nat. Rev. Cancer 2011, 11:726-734.
20. Suva M.L., Riggi N., Bernstein B.E. Epigenetic reprogramming in cancer. Science 2013, 339:1567-1570.
21. Bergman Y., Cedar H. DNA methylation dynamics in health and disease. Nat. Struct. Mol. Biol. 2013, 20:274-281.
22. Watson I.R., Takahashi K., Futreal P.A., Chin L. Emerging patterns of somatic mutations in cancer. Nat. Rev. Genet. 2013, 14:703-718.
23. Forbes S.A., Bindal N., Bamford S., Cole C., Kok C.Y., Beare D., Jia M., Shepherd R., Leung K., Menzies A., Teague J.W., Campbell P.J., Stratton M.R., Futreal P.A. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 2011, 39:D945-D950.
24. Greer E.L., Shi Y. Histone methylation: a dynamic mark in health, disease and inheritance. Nat. Rev. Genet. 2012, 13:343-357.
25. Yoo C.B., Jones P.A. Epigenetic therapy of cancer: past, present and future. Nat. Rev. Drug. Discov. 2006, 5:37-50.
26. Kim S.J., Zhao H., Hardikar S., Singh A.K., Goodell M.A., Chen T. A DNMT3A mutation common in AML exhibits dominant-negative effects in murine ES cells. Blood 2013, 122:4086-4089.
27. Russler-Germain D.A., Spencer D.H., Young M.A., Lamprecht T.L., Miller C.A., Fulton R., Meyer M.R., Erdmann-Gilmore P., Townsend R.R., Wilson R.K., Ley T.J. The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers. Cancer Cell 2014, 25:442-454.
28. Ko M., Huang Y., Jankowska A.M., Pape U.J., Tahiliani M., Bandukwala H.S., An J., Lamperti E.D., Koh K.P., Ganetzky R., Liu X.S., Aravind L., Agarwal S., Maciejewski J.P., Rao A. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010, 468:839-843.
29. Tefferi A., Lim K.H., Levine R. Mutation in TET2 in myeloid cancers. N. Engl. J. Med. 2009, 361:1117. (author reply 1117-1118.).
30. Chan S.M., Majeti R. Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia. Int. J. Hematol. 2013, 98:648-657.
31. Yan H., Parsons D.W., Jin G., McLendon R., Rasheed B.A., Yuan W., Kos I., Batinic-Haberle I., Jones S., Riggins G.J., Friedman H., Friedman A., Reardon D., Herndon J., Kinzler K.W., Velculescu V.E., Vogelstein B., Bigner D.D. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 2009, 360:765-773.
32. Dang L., White D.W., Gross S., Bennett B.D., Bittinger M.A., Driggers E.M., Fantin V.R., Jang H.G., Jin S., Keenan M.C., Marks K.M., Prins R.M., Ward P.S., Yen K.E., Liau L.M., Rabinowitz J.D., Cantley L.C., Thompson C.B., Vander Heiden M.G., Su S.M. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009, 462:739-744.
33. Ito S., D'Alessio A.C., Taranova O.V., Hong K., Sowers L.C., Zhang Y. Role of TET proteins in 5mC to 5hmC conversion ES-cell self-renewal and inner cell mass specification. Nature 2010, 466:1129-1133.
34. Tahiliani M., Koh K.P., Shen Y., Pastor W.A., Bandukwala H., Brudno Y., Agarwal S., Iyer L.M., Liu D.R., Aravind L., Rao A. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009, 324:930-935.
35. Xu W., Yang H., Liu Y., Yang Y., Wang P., Kim S.H., Ito S., Yang C., Wang P., Xiao M.T., Liu L.X., Jiang W.Q., Liu J., Zhang J.Y., Wang B., Frye S., Zhang Y., Xu Y.H., Lei Q.Y., Guan K.L., Zhao S.M., Xiong Y. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 2011, 19:17-30.
36. Figueroa M.E., Abdel-Wahab O., Lu C., Ward P.S., Patel J., Shih A., Li Y., Bhagwat N., Vasanthakumar A., Fernandez H.F., Tallman M.S., Sun Z., Wolniak K., Peeters J.K., Liu W., Choe S.E., Fantin V.R., Paietta E., Lowenberg B., Licht J.D., Godley L.A., Delwel R., Valk P.J., Thompson C.B., Levine R.L., Melnick A. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010, 18:553-567.
37. Hohmann A.F., Vakoc C.R. A rationale to target the SWI/SNF complex for cancer therapy. Trends Genet. 2014, 30:356-363.
38. Rathert P., Dhayalan A., Murakami M., Zhang X., Tamas R., Jurkowska R., Komatsu Y., Shinkai Y., Cheng X., Jeltsch A. Protein lysine methyltransferase G9a acts on non-histone targets. Nat. Chem. Biol. 2008, 4:344-346.
39. Dhayalan A., Kudithipudi S., Rathert P., Jeltsch A. Specificity analysis-based identification of new methylation targets of the SET7/9 protein lysine methyltransferase. Chem. Biol. 2011, 18:111-120.
40. Clarke S.G. Protein methylation at the surface and buried deep: thinking outside the histone box. Trends Biochem. Sci. 2013, 38:243-252.
41. Lanouette S., Mongeon V., Figeys D., Couture J.F. The functional diversity of protein lysine methylation. Mol. Syst. Biol. 2014, 10:724.
42. Moore K.E., Gozani O. An unexpected journey: lysine methylation across the proteome. Biochim. Biophys. Acta 2014, (in press).
43. Muller J., Kassis J.A. Polycomb response elements and targeting of Polycomb group proteins in Drosophila. Curr. Opin. Genet. Dev. 2006, 16:476-484.
44. Margueron R., Reinberg D. The Polycomb complex PRC2 and its mark in life. Nature 2011, 469:343-349.
45. Cao R., Zhang Y. The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. Curr. Opin. Genet. Dev. 2004, 14:155-164.
46. Margueron R., Li G., Sarma K., Blais A., Zavadil J., Woodcock C.L., Dynlacht B.D., Reinberg D. Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms. Mol. Cell 2008, 32:503-518.
47. Simon J.A., Lange C.A. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat. Res. 2008, 647:21-29.
48. McCabe M.T., Ott H.M., Ganji G., Korenchuk S., Thompson C., Van Aller G.S., Liu Y., Graves A.P., Della Pietra A., Diaz E., LaFrance L.V., Mellinger M., Duquenne C., Tian X., Kruger R.G., McHugh C.F., Brandt M., Miller W.H., Dhanak D., Verma S.K., Tummino P.J., Creasy C.L. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012, 492:108-112.
49. Ntziachristos P., Tsirigos A., Van Vlierberghe P., Nedjic J., Trimarchi T., Flaherty M.S., Ferres-Marco D., da Ros V., Tang Z., Siegle J., Asp P., Hadler M., Rigo I., De Keersmaecker K., Patel J., Huynh T., Utro F., Poglio S., Samon J.B., Paietta E., Racevskis J., Rowe J.M., Rabadan R., Levine R.L., Brown S., Pflumio F., Dominguez M., Ferrando A., Aifantis I. Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat. Med. 2012, 18:298-301.
50. He A., Shen X., Ma Q., Cao J., von Gise A., Zhou P., Wang G., Marquez V.E., Orkin S.H., Pu W.T. PRC2 directly methylates GATA4 and represses its transcriptional activity. Genes Dev. 2012, 26:37-42.
51. Lee J.M., Lee J.S., Kim H., Kim K., Park H., Kim J.Y., Lee S.H., Kim I.S., Kim J., Lee M., Chung C.H., Seo S.B., Yoon J.B., Ko E., Noh D.Y., Kim K.I., Kim K.K., Baek S.H. EZH2 generates a methyl degron that is recognized by the DCAF1/DDB1/CUL4 E3 ubiquitin ligase complex. Mol. Cell 2012, 48:572-586.
52. Morin R.D., Johnson N.A., Severson T.M., Mungall A.J., An J., Goya R., Paul J.E., Boyle M., Woolcock B.W., Kuchenbauer F., Yap D., Humphries R.K., Griffith O.L., Shah S., Zhu H., Kimbara M., Shashkin P., Charlot J.F., Tcherpakov M., Corbett R., Tam A., Varhol R., Smailus D., Moksa M., Zhao Y., Delaney A., Qian H., Birol I., Schein J., Moore R., Holt R., Horsman D.E., Connors J.M., Jones S., Aparicio S., Hirst M., Gascoyne R.D., Marra M.A. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat. Genet. 2010, 42:181-185.
53. Ryan R.J., Nitta M., Borger D., Zukerberg L.R., Ferry J.A., Harris N.L., Iafrate A.J., Bernstein B.E., Sohani A.R., Le L.P. EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas. PLoS ONE 2011, 6:e28585.
54. Sneeringer C.J., Scott M.P., Kuntz K.W., Knutson S.K., Pollock R.M., Richon V.M., Copeland R.A. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:20980-20985.
55. Collins R.E., Tachibana M., Tamaru H., Smith K.M., Jia D., Zhang X., Selker E.U., Shinkai Y., Cheng X. In vitro and in vivo analyses of a Phe/Tyr switch controlling product specificity of histone lysine methyltransferases. J. Biol. Chem. 2005, 280:5563-5570.
56. Yap D.B., Chu J., Berg T., Schapira M., Cheng S.W., Moradian A., Morin R.D., Mungall A.J., Meissner B., Boyle M., Marquez V.E., Marra M.A., Gascoyne R.D., Humphries R.K., Arrowsmith C.H., Morin G.B., Aparicio S.A. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 2011, 117:2451-2459.
57. McCabe M.T., Graves A.P., Ganji G., Diaz E., Halsey W.S., Jiang Y., Smitheman K.N., Ott H.M., Pappalardi M.B., Allen K.E., Chen S.B., Della Pietra A., Dul E., Hughes A.M., Gilbert S.A., Thrall S.H., Tummino P.J., Kruger R.G., Brandt M., Schwartz B., Creasy C.L. Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proc. Natl. Acad. Sci. U. S. A. 2012, 109:2989-2994.
58. Knutson S.K., Wigle T.J., Warholic N.M., Sneeringer C.J., Allain C.J., Klaus C.R., Sacks J.D., Raimondi A., Majer C.R., Song J., Scott M.P., Jin L., Smith J.J., Olhava E.J., Chesworth R., Moyer M.P., Richon V.M., Copeland R.A., Keilhack H., Pollock R.M., Kuntz K.W. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat. Chem. Biol. 2012, 8:890-896.
59. Huether R., Dong L., Chen X., Wu G., Parker M., Wei L., Ma J., Edmonson M.N., Hedlund E.K., Rusch M.C., Shurtleff S.A., Mulder H.L., Boggs K., Vadordaria B., Cheng J., Yergeau D., Song G., Becksfort J., Lemmon G., Weber C., Cai Z., Dang J., Walsh M., Gedman A.L., Faber Z., Easton J., Gruber T., Kriwacki R.W., Partridge J.F., Ding L., Wilson R.K., Mardis E.R., Mullighan C.G., Gilbertson R.J., Baker S.J., Zambetti G., Ellison D.W., Zhang J., Downing J.R. The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes. Nat. Commun. 2014, 5:3630.
60. Ansari K.I., Mishra B.P., Mandal S.S. MLL histone methylases in gene expression, hormone signaling and cell cycle. Front. Biosci. (Landmark Ed) 2009, 14:3483-3495.
61. Bogershausen N., Bruford E., Wollnik B. Skirting the pitfalls: a clear-cut nomenclature for H3K4 methyltransferases. Clin. Genet. 2013, 83:212-214.
62. Cheng J., Blum R., Bowman C., Hu D., Shilatifard A., Shen S., Dynlacht B.D. A role for H3K4 monomethylation in gene repression and partitioning of chromatin readers. Mol. Cell 2014, 53:979-992.
63. Sebastian S., Sreenivas P., Sambasivan R., Cheedipudi S., Kandalla P., Pavlath G.K., Dhawan J. MLL5, a trithorax homolog, indirectly regulates H3K4 methylation, represses cyclin A2 expression, and promotes myogenic differentiation. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:4719-4724.
64. Southall S.M., Wong P.S., Odho Z., Roe S.M., Wilson J.R. Structural basis for the requirement of additional factors for MLL1 SET domain activity and recognition of epigenetic marks. Mol. Cell 2009, 33:181-191.
65. Wang P., Lin C., Smith E.R., Guo H., Sanderson B.W., Wu M., Gogol M., Alexander T., Seidel C., Wiedemann L.M., Ge K., Krumlauf R., Shilatifard A. Global analysis of H3K4 methylation defines MLL family member targets and points to a role for MLL1-mediated H3K4 methylation in the regulation of transcriptional initiation by RNA polymerase II. Mol. Cell. Biol. 2009, 29:6074-6085.
66. Daser A., Rabbitts T.H. The versatile mixed lineage leukaemia gene MLL and its many associations in leukaemogenesis. Semin. Cancer Biol. 2005, 15:175-188.
67. Krivtsov A.V., Armstrong S.A. MLL translocations, histone modifications and leukaemia stem-cell development. Nat. Rev. Cancer 2007, 7:823-833.
68. Anglin J.L., Song Y. A medicinal chemistry perspective for targeting histone H3 lysine-79 methyltransferase DOT1L. J. Med. Chem. 2013, 56:8972-8983.
69. Muntean A.G., Hess J.L. The pathogenesis of mixed-lineage leukemia. Annu. Rev. Pathol. 2012, 7:283-301.
70. Ansari K.I., Kasiri S., Mandal S.S. Histone methylase MLL1 has critical roles in tumor growth and angiogenesis and its knockdown suppresses tumor growth in vivo. Oncogene 2013, 32:3359-3370.
71. Ruault M., Brun M.E., Ventura M., Roizes G., De Sario A. MLL3, a new human member of the TRX/MLL gene family, maps to 7q36, a chromosome region frequently deleted in myeloid leukaemia. Gene 2002, 284:73-81.
72. Lee J., Kim D.H., Lee S., Yang Q.H., Lee D.K., Lee S.K., Roeder R.G., Lee J.W. A tumor suppressive coactivator complex of p53 containing ASC-2 and histone H3-lysine-4 methyltransferase MLL3 or its paralogue MLL4. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:8513-8518.
73. Wang X.X., Fu L., Li X., Wu X., Zhu Z., Fu L., Dong J.T. Somatic mutations of the mixed-lineage leukemia 3 (MLL3) gene in primary breast cancers. Pathol. Oncol. Res. 2011, 17:429-433.
74. Watanabe Y., Castoro R.J., Kim H.S., North B., Oikawa R., Hiraishi T., Ahmed S.S., Chung W., Cho M.Y., Toyota M., Itoh F., Estecio M.R., Shen L., Jelinek J., Issa J.P. Frequent alteration of MLL3 frameshift mutations in microsatellite deficient colorectal cancer. PLoS ONE 2011, 6:e23320.
75. Balakrishnan A., Bleeker F.E., Lamba S., Rodolfo M., Daniotti M., Scarpa A., van Tilborg A.A., Leenstra S., Zanon C., Bardelli A. Novel somatic and germline mutations in cancer candidate genes in glioblastoma, melanoma, and pancreatic carcinoma. Cancer Res. 2007, 67:3545-3550.
76. Sjoblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K., Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., Velculescu V.E. The consensus coding sequences of human breast and colorectal cancers. Science 2006, 314:268-274.
77. Green M.R., Gentles A.J., Nair R.V., Irish J.M., Kihira S., Liu C.L., Kela I., Hopmans E.S., Myklebust J.H., Ji H., Plevritis S.K., Levy R., Alizadeh A.A. Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. Blood 2013, 121:1604-1611.
78. Parsons D.W., Li M., Zhang X., Jones S., Leary R.J., Lin J.C., Boca S.M., Carter H., Samayoa J., Bettegowda C., Gallia G.L., Jallo G.I., Binder Z.A., Nikolsky Y., Hartigan J., Smith D.R., Gerhard D.S., Fults D.W., VandenBerg S., Berger M.S., Marie S.K., Shinjo S.M., Clara C., Phillips P.C., Minturn J.E., Biegel J.A., Judkins A.R., Resnick A.C., Storm P.B., Curran T., He Y., Rasheed B.A., Friedman H.S., Keir S.T., McLendon R., Northcott P.A., Taylor M.D., Burger P.C., Riggins G.J., Karchin R., Parmigiani G., Bigner D.D., Yan H., Papadopoulos N., Vogelstein B., Kinzler K.W., Velculescu V.E. The genetic landscape of the childhood cancer medulloblastoma. Science 2011, 331:435-439.
79. Singer M.S., Kahana A., Wolf A.J., Meisinger L.L., Peterson S.E., Goggin C., Mahowald M., Gottschling D.E. Identification of high-copy disruptors of telomeric silencing in Saccharomyces cerevisiae. Genetics 1998, 150:613-632.
80. van Leeuwen F., Gafken P.R., Gottschling D.E. Dot1p modulates silencing in yeast by methylation of the nucleosome core. Cell 2002, 109:745-756.
81. Lacoste N., Utley R.T., Hunter J.M., Poirier G.G., Cote J. Disruptor of telomeric silencing-1 is a chromatin-specific histone H3 methyltransferase. J. Biol. Chem. 2002, 277:30421-30424.
82. Feng Q., Wang H., Ng H.H., Erdjument-Bromage H., Tempst P., Struhl K., Zhang Y. Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain. Curr. Biol. 2002, 12:1052-1058.
83. Min J., Feng Q., Li Z., Zhang Y., Xu R.M. Structure of the catalytic domain of human DOT1L, a non-SET domain nucleosomal histone methyltransferase. Cell 2003, 112:711-723.
84. Schubert H.L., Blumenthal R.M., Cheng X. Many paths to methyltransfer: a chronicle of convergence. Trends Biochem. Sci. 2003, 28:329-335.
85. Kernstock S., Davydova E., Jakobsson M., Moen A., Pettersen S., Maelandsmo G.M., Egge-Jacobsen W., Falnes P.O. Lysine methylation of VCP by a member of a novel human protein methyltransferase family. Nat. Commun. 2012, 3:1038.
86. Frederiks F., Tzouros M., Oudgenoeg G., van Welsem T., Fornerod M., Krijgsveld J., van Leeuwen F. Nonprocessive methylation by Dot1 leads to functional redundancy of histone H3K79 methylation states. Nat. Struct. Mol. Biol. 2008, 15:550-557.
87. Nguyen A.T., Zhang Y. The diverse functions of Dot1 and H3K79 methylation. Genes Dev. 2011, 25:1345-1358.
88. Steger D.J., Lefterova M.I., Ying L., Stonestrom A.J., Schupp M., Zhuo D., Vakoc A.L., Kim J.E., Chen J., Lazar M.A., Blobel G.A., Vakoc C.R. DOT1L/KMT4 recruitment and H3K79 methylation are ubiquitously coupled with gene transcription in mammalian cells. Mol. Cell. Biol. 2008, 28:2825-2839.
89. Jones B., Su H., Bhat A., Lei H., Bajko J., Hevi S., Baltus G.A., Kadam S., Zhai H., Valdez R., Gonzalo S., Zhang Y., Li E., Chen T. The histone H3K79 methyltransferase Dot1L is essential for mammalian development and heterochromatin structure. PLoS Genet. 2008, 4:e1000190.
90. Okada Y., Feng Q., Lin Y., Jiang Q., Li Y., Coffield V.M., Su L., Xu G., Zhang Y. hDOT1L links histone methylation to leukemogenesis. Cell 2005, 121:167-178.
91. Chen L., Deshpande A.J., Banka D., Bernt K.M., Dias S., Buske C., Olhava E.J., Daigle S.R., Richon V.M., Pollock R.M., Armstrong S.A. Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l. Leukemia 2013, 27:813-822.
92. Daigle S.R., Olhava E.J., Therkelsen C.A., Majer C.R., Sneeringer C.J., Song J., Johnston L.D., Scott M.P., Smith J.J., Xiao Y., Jin L., Kuntz K.W., Chesworth R., Moyer M.P., Bernt K.M., Tseng J.C., Kung A.L., Armstrong S.A., Copeland R.A., Richon V.M., Pollock R.M. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 2011, 20:53-65.
93. Travers J., Blagg J., Workman P. Epigenetics: targeting leukemia on the DOT. Nat. Chem. Biol. 2011, 7:663-665.
94. Bernt K.M., Zhu N., Sinha A.U., Vempati S., Faber J., Krivtsov A.V., Feng Z., Punt N., Daigle A., Bullinger L., Pollock R.M., Richon V.M., Kung A.L., Armstrong S.A. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 2011, 20:66-78.
95. Kim W., Kim R., Park G., Park J.W., Kim J.E. Deficiency of H3K79 histone methyltransferase Dot1-like protein (DOT1L) inhibits cell proliferation. J. Biol. Chem. 2012, 287:5588-5599.
96. Rega S., Stiewe T., Chang D.I., Pollmeier B., Esche H., Bardenheuer W., Marquitan G., Putzer B.M. Identification of the full-length huntingtin-interacting protein p231HBP/HYPB as a DNA-binding factor. Mol. Cell. Neurosci. 2001, 18:68-79.
97. Sun X.J., Wei J., Wu X.Y., Hu M., Wang L., Wang H.H., Zhang Q.H., Chen S.J., Huang Q.H., Chen Z. Identification and characterization of a novel human histone H3 lysine 36-specific methyltransferase. J. Biol. Chem. 2005, 280:35261-35271.
98. Wagner E.J., Carpenter P.B. Understanding the language of Lys36 methylation at histone. Nat. Rev. Mol. Cell Biol. 2012, 13:115-126.
99. Edmunds J.W., Mahadevan L.C., Clayton A.L. Dynamic histone H3 methylation during gene induction: HYPB/Setd2 mediates all H3K36 trimethylation. EMBO J. 2008, 27:406-420.
100. Xie P., Tian C., An L., Nie J., Lu K., Xing G., Zhang L., He F. Histone methyltransferase protein SETD2 interacts with p53 and selectively regulates its downstream genes. Cell. Signal. 2008, 20:1671-1678.
101. Al Sarakbi W., Sasi W., Jiang W.G., Roberts T., Newbold R.F., Mokbel K. The mRNA expression of SETD2 in human breast cancer: correlation with clinico-pathological parameters. BMC Cancer 2009, 9:290.
102. Newbold R.F., Mokbel K. Evidence for a tumour suppressor function of SETD2 in human breast cancer: a new hypothesis. Anticancer Res. 2010, 30:3309-3311.
103. Fontebasso A.M., Schwartzentruber J., Khuong-Quang D.A., Liu X.Y., Sturm D., Korshunov A., Jones D.T., Witt H., Kool M., Albrecht S., Fleming A., Hadjadj D., Busche S., Lepage P., Montpetit A., Staffa A., Gerges N., Zakrzewska M., Zakrzewski K., Liberski P.P., Hauser P., Garami M., Klekner A., Bognar L., Zadeh G., Faury D., Pfister S.M., Jabado N., Majewski J. Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas. Acta Neuropathol. 2013, 125:659-669.
104. Mar B.G., Bullinger L.B., McLean K.M., Grauman P.V., Harris M.H., Stevenson K., Neuberg D.S., Sinha A.U., Sallan S.E., Silverman L.B., Kung A.L., Lo Nigro L., Ebert B.L., Armstrong S.A. Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia. Nat. Commun. 2014, 5:3469.
105. Zhu X., He F., Zeng H., Ling S., Chen A., Wang Y., Yan X., Wei W., Pang Y., Cheng H., Hua C., Zhang Y., Yang X., Lu X., Cao L., Hao L., Dong L., Zou W., Wu J., Li X., Zheng S., Yan J., Zhou J., Zhang L., Mi S., Wang X., Zou Y., Chen Y., Geng Z., Wang J., Liu X., Yuan W., Huang G., Cheng T., Wang Q.F. Identification of functional cooperative mutations of SETD2 in human acute leukemia. Nat. Genet. 2014, 46:287-293.
106. Duns G., van den Berg E., van Duivenbode I., Osinga J., Hollema H., Hofstra R.M., Kok K. Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma. Cancer Res. 2010, 70:4287-4291.
107. Rayasam G.V., Wendling O., Angrand P.O., Mark M., Niederreither K., Song L., Lerouge T., Hager G.L., Chambon P., Losson R. NSD1 is essential for early post-implantation development and has a catalytically active SET domain. EMBO J. 2003, 22:3153-3163.
108. Huang S., Shao G., Liu L. The PR domain of the Rb-binding zinc finger protein RIZ1 is a protein binding interface and is related to the SET domain functioning in chromatin-mediated gene expression. J. Biol. Chem. 1998, 273:15933-15939.
109. Lucio-Eterovic A.K., Singh M.M., Gardner J.E., Veerappan C.S., Rice J.C., Carpenter P.B. Role for the nuclear receptor-binding SET domain protein 1 (NSD1) methyltransferase in coordinating lysine 36 methylation at histone 3 with RNA polymerase II function. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:16952-16957.
110. Stec I., Wright T.J., van Ommen G.J., de Boer P.A., van Haeringen A., Moorman A.F., Altherr M.R., den Dunnen J.T. WHSC1, a 90kb SET domain-containing gene, expressed in early development and homologous to a Drosophila dysmorphy gene maps in the Wolf-Hirschhorn syndrome critical region and is fused to IgH in t(4;14) multiple myeloma. Hum. Mol. Genet. 1998, 7:1071-1082.
111. Chesi M., Nardini E., Lim R.S., Smith K.D., Kuehl W.M., Bergsagel P.L. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene MMSET, resulting in IgH/MMSET hybrid transcripts. Blood 1998, 92:3025-3034.
112. Angrand P.O., Apiou F., Stewart A.F., Dutrillaux B., Losson R., Chambon P. NSD3, a new SET domain-containing gene, maps to 8p12 and is amplified in human breast cancer cell lines. Genomics 2001, 74:79-88.
113. Kim S.M., Kee H.J., Eom G.H., Choe N.W., Kim J.Y., Kim Y.S., Kim S.K., Kook H., Seo S.B. Characterization of a novel WHSC1-associated SET domain protein with H3K4 and H3K27 methyltransferase activity. Biochem. Biophys. Res. Commun. 2006, 345:318-323.
114. Marango J., Shimoyama M., Nishio H., Meyer J.A., Min D.J., Sirulnik A., Martinez-Martinez Y., Chesi M., Bergsagel P.L., Zhou M.M., Waxman S., Leibovitch B.A., Walsh M.J., Licht J.D. The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor. Blood 2008, 111:3145-3154.
115. Kang H.B., Choi Y., Lee J.M., Choi K.C., Kim H.C., Yoo J.Y., Lee Y.H., Yoon H.G. The histone methyltransferase, NSD2, enhances androgen receptor-mediated transcription. FEBS Lett. 2009, 583:1880-1886.
116. Li Y., Trojer P., Xu C.F., Cheung P., Kuo A., Drury W.J., Qiao Q., Neubert T.A., Xu R.M., Gozani O., Reinberg D. The target of the NSD family of histone lysine methyltransferases depends on the nature of the substrate. J. Biol. Chem. 2009, 284:34283-34295.
117. Pei H., Zhang L., Luo K., Qin Y., Chesi M., Fei F., Bergsagel P.L., Wang L., You Z., Lou Z. MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites. Nature 2011, 470:124-128.
118. Kuo A.J., Cheung P., Chen K.F., Zee B.M., Kioi M., Lauring J., Xi Y.X., Park B.H., Shi X.B., Garcia B.A., Li W., Gozani O. NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming. Mol. Cell 2011, 44:609-620.
119. Kudithipudi S., Lungu C., Rathert P., Happel N., Jeltsch A. Substrate specificity analysis and novel substrates of the protein lysine methyltransferase NSD1. Chem. Biol. 2014, 21:226-237.
120. Douglas J., Hanks S., Temple I.K., Davies S., Murray A., Upadhyaya M., Tomkins S., Hughes H.E., Cole T.R., Rahman N. NSD1 mutations are the major cause of Sotos syndrome and occur in some cases of Weaver syndrome but are rare in other overgrowth phenotypes. Am. J. Hum. Genet. 2003, 72:132-143.
121. Nimura K., Ura K., Shiratori H., Ikawa M., Okabe M., Schwartz R.J., Kaneda Y. A histone H3 lysine 36 trimethyltransferase links Nkx2-5 to Wolf-Hirschhorn syndrome. Nature 2009, 460:287-291.
122. Morishita M., di Luccio E. Cancers and the NSD family of histone lysine methyltransferases. Biochim. Biophys. Acta 2011, 1816:158-163.
123. Hudlebusch H.R., Skotte J., Santoni-Rugiu E., Zimling Z.G., Lees M.J., Simon R., Sauter G., Rota R., De Ioris M.A., Quarto M., Johansen J.V., Jorgensen M., Rechnitzer C., Maroun L.L., Schroder H., Petersen B.L., Helin K. MMSET is highly expressed and associated with aggressiveness in neuroblastoma. Cancer Res. 2011, 71:4226-4235.
124. Jaffe J.D., Wang Y., Chan H.M., Zhang J., Huether R., Kryukov G.V., Bhang H.E., Taylor J.E., Hu M., Englund N.P., Yan F., Wang Z., Robert McDonald E., Wei L., Ma J., Easton J., Yu Z., de Beaumount R., Gibaja V., Venkatesan K., Schlegel R., Sellers W.R., Keen N., Liu J., Caponigro G., Barretina J., Cooke V.G., Mullighan C., Carr S.A., Downing J.R., Garraway L.A., Stegmeier F. Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia. Nat. Genet. 2013, 45:1386-1391.
125. Wang G.G., Cai L., Pasillas M.P., Kamps M.P. NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis. Nat. Cell Biol. 2007, 9:804-812.
126. Oyer J.A., Huang X., Zheng Y., Shim J., Ezponda T., Carpenter Z., Allegretta M., Okot-Kotber C.I., Patel J.P., Melnick A., Levine R.L., Ferrando A., Mackerell A.D., Kelleher N.L., Licht J.D., Popovic R. Point mutation E1099K in MMSET/NSD2 enhances its methyltranferase activity and leads to altered global chromatin methylation in lymphoid malignancies. Leukemia 2014, 28:198-201.
127. Wu J., Cheung T., Grande C., Ferguson A.D., Zhu X., Theriault K., Code E., Birr C., Keen N., Chen H. Biochemical characterization of human SET and MYND domain-containing protein 2 methyltransferase. Biochemistry 2011, 50:6488-6497.
128. Tan X., Rotllant J., Li H., De Deyne P., Du S.J. SmyD1, a histone methyltransferase, is required for myofibril organization and muscle contraction in zebrafish embryos. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:2713-2718.
129. Hamamoto R., Furukawa Y., Morita M., Iimura Y., Silva F.P., Li M., Yagyu R., Nakamura Y. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat. Cell Biol. 2004, 6:731-740.
130. Brown M.A., Sims R.J., Gottlieb P.D., Tucker P.W. Identification and characterization of Smyd2: a split SET/MYND domain-containing histone H3 lysine 36-specific methyltransferase that interacts with the Sin3 histone deacetylase complex. Mol. Cancer 2006, 5:26.
131. Abu-Farha M., Lambert J.P., Al-Madhoun A.S., Elisma F., Skerjanc I.S., Figeys D. The tale of two domains: proteomics and genomics analysis of SMYD2, a new histone methyltransferase. Mol. Cell. Proteomics 2008, 7:560-572.
132. Zhang X., Tanaka K., Yan J., Li J., Peng D., Jiang Y., Yang Z., Barton M.C., Wen H., Shi X. Regulation of estrogen receptor alpha by histone methyltransferase SMYD2-mediated protein methylation. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:17284-17289.
133. Huang J., Perez-Burgos L., Placek B.J., Sengupta R., Richter M., Dorsey J.A., Kubicek S., Opravil S., Jenuwein T., Berger S.L. Repression of p53 activity by Smyd2-mediated methylation. Nature 2006, 444:629-632.
134. Saddic L.A., West L.E., Aslanian A., Yates J.R., Rubin S.M., Gozani O., Sage J. Methylation of the retinoblastoma tumor suppressor by SMYD2. J. Biol. Chem. 2010, 285:37733-37740.
135. Cho H.S., Hayami S., Toyokawa G., Maejima K., Yamane Y., Suzuki T., Dohmae N., Kogure M., Kang D., Neal D.E., Ponder B.A., Yamaue H., Nakamura Y., Hamamoto R. RB1 methylation by SMYD2 enhances cell cycle progression through an increase of RB1 phosphorylation. Neoplasia 2012, 14:476-486.
136. Sakamoto L.H., Andrade R.V., Felipe M.S., Motoyama A.B., Pittella Silva F. SMYD2 is highly expressed in pediatric acute lymphoblastic leukemia and constitutes a bad prognostic factor. Leuk. Res. 2014, 38:496-502.
137. Komatsu S., Imoto I., Tsuda H., Kozaki K.I., Muramatsu T., Shimada Y., Aiko S., Yoshizumi Y., Ichikawa D., Otsuji E., Inazawa J. Overexpression of SMYD2 relates to tumor cell proliferation and malignant outcome of esophageal squamous cell carcinoma. Carcinogenesis 2009, 30:1139-1146.
138. Hu L., Zhu Y.T., Qi C., Zhu Y.J. Identification of Smyd4 as a potential tumor suppressor gene involved in breast cancer development. Cancer Res. 2009, 69:4067-4072.
139. Foreman K.W., Brown M., Park F., Emtage S., Harriss J., Das C., Zhu L., Crew A., Arnold L., Shaaban S., Tucker P. Structural and functional profiling of the human histone methyltransferase SMYD3. PLoS ONE 2011, 6:e22290.
140. Van Aller G.S., Reynoird N., Barbash O., Huddleston M., Liu S., Zmoos A.F., McDevitt P., Sinnamon R., Le B., Mas G., Annan R., Sage J., Garcia B.A., Tummino P.J., Gozani O., Kruger R.G. Smyd3 regulates cancer cell phenotypes and catalyzes histone H4 lysine 5 methylation. Epigenetics 2012, 7:340-343.
141. Silva F.P., Hamamoto R., Kunizaki M., Tsuge M., Nakamura Y., Furukawa Y. Enhanced methyltransferase activity of SMYD3 by the cleavage of its N-terminal region in human cancer cells. Oncogene 2008, 27:2686-2692.
142. Cock-Rada A.M., Medjkane S., Janski N., Yousfi N., Perichon M., Chaussepied M., Chluba J., Langsley G., Weitzman J.B. SMYD3 promotes cancer invasion by epigenetic upregulation of the metalloproteinase MMP-9. Cancer Res. 2012, 72:810-820.
143. Mazur P.K., Reynoird N., Khatri P., Jansen P.W., Wilkinson A.W., Liu S., Barbash O., Van Aller G.S., Huddleston M., Dhanak D., Tummino P.J., Kruger R.G., Garcia B.A., Butte A.J., Vermeulen M., Sage J., Gozani O. SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer. Nature 2014, 510:283-287.
144. Stransky N., Egloff A.M., Tward A.D., Kostic A.D., Cibulskis K., Sivachenko A., Kryukov G.V., Lawrence M.S., Sougnez C., McKenna A., Shefler E., Ramos A.H., Stojanov P., Carter S.L., Voet D., Cortes M.L., Auclair D., Berger M.F., Saksena G., Guiducci C., Onofrio R.C., Parkin M., Romkes M., Weissfeld J.L., Seethala R.R., Wang L., Rangel-Escareno C., Fernandez-Lopez J.C., Hidalgo-Miranda A., Melendez-Zajgla J., Winckler W., Ardlie K., Gabriel S.B., Meyerson M., Lander E.S., Getz G., Golub T.R., Garraway L.A., Grandis J.R. The mutational landscape of head and neck squamous cell carcinoma. Science 2011, 333:1157-1160.
145. Seshagiri S., Stawiski E.W., Durinck S., Modrusan Z., Storm E.E., Conboy C.B., Chaudhuri S., Guan Y., Janakiraman V., Jaiswal B.S., Guillory J., Ha C., Dijkgraaf G.J., Stinson J., Gnad F., Huntley M.A., Degenhardt J.D., Haverty P.M., Bourgon R., Wang W., Koeppen H., Gentleman R., Starr T.K., Zhang Z., Largaespada D.A., Wu T.D., de Sauvage F.J. Recurrent R-spondin fusions in colon cancer. Nature 2012, 488:660-664.
146. Imielinski M., Berger A.H., Hammerman P.S., Hernandez B., Pugh T.J., Hodis E., Cho J., Suh J., Capelletti M., Sivachenko A., Sougnez C., Auclair D., Lawrence M.S., Stojanov P., Cibulskis K., Choi K., de Waal L., Sharifnia T., Brooks A., Greulich H., Banerji S., Zander T., Seidel D., Leenders F., Ansen S., Ludwig C., Engel-Riedel W., Stoelben E., Wolf J., Goparju C., Thompson K., Winckler W., Kwiatkowski D., Johnson B.E., Janne P.A., Miller V.A., Pao W., Travis W.D., Pass H.I., Gabriel S.B., Lander E.S., Thomas R.K., Garraway L.A., Getz G., Meyerson M. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012, 150:1107-1120.
147. You J.S., Jones P.A. Cancer genetics and epigenetics: two sides of the same coin?. Cancer Cell 2012, 22:9-20.